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Abstract VAMPs are vesicle associated membrane proteins
that are essential for secretion. A spliced isoform of rat VAMP-
2, called VAMP-2B, is characterized in this study. The VAMP-
2B transcript is the result of alternative RNA splicing in which an
intron is retained. The predicted amino acid sequence of VAMP-
2B differs from VAMP-2 at its carboxy-terminal end. Because
recent studies have shown that VAMP’s carboxy-terminal end
influences the protein’s sorting, the location of myc-epitope
tagged VAMP-2B in PC12 cells was determined. Subcellular
fractionation showed colocalization of myc-VAMP-2B and
endogenous VAMP-2. Thus alternative RNA splicing does not
affect VAMP-2 sorting in PC12 cells.
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1. Introduction
Vesicle associated membrane proteins (VAMPs), also
known as synaptobrevins, were initially characterized in syn-
aptic vesicles [1,2] and represent a conserved protein family
from yeast to mammals [3^5]. The VAMPs are type II mem-
brane proteins that are essential for the vesicle mediated trans-
port of proteins [3,6,7]. As described in the SNARE hypoth-
esis, VAMPs that are present on transport vesicles will bind to
t-SNAREs represented by syntaxin and SNAP-25 on the tar-
get membrane [8]. Potential functions proposed for the
VAMP protein family include a role in the targeting, docking,
or fusion of transport vesicles with the target membrane [7,9^
11]. Although initially characterized in synaptic vesicles, the
VAMPs have also been detected in non-neural tissues [12^14].
The recent characterization of several new mammalian VAMP
isoforms that each occupy a di¡erent subcellular compartment
provides support for VAMP’s role in mediating transport in
di¡erent intracellular pathways [14].
Several studies have focused on the identi¢cation of VAMP
domains responsible for targeting the VAMPs to di¡erent
subcellular compartments. Data supporting the presence of
a sorting signal within the cytoplasmic domain of VAMP-2
was obtained when mutations introduced into the protein’s
cytoplasmic domain disrupted its sorting into a synaptic
vesicle compartment in the neuroendocrine cell line, PC12
[15]. Ossig et al. demonstrated that the transmembrane and
carboxy-terminal end of the yeast VAMP homologue, Snc1p,
may serve as a sorting domain for VAMP homologues in
yeast [16].
Alternative RNA splicing has been demonstrated in Droso-
phila and mammalian cells as one means of expanding the
diversity of VAMP isoforms [17^19]. The alternative RNA
splicings described to date for the VAMPs all a¡ect the car-
boxy-terminal end of the protein, speci¢cally the domain that
putatively extends into the vesicle lumen. We have previously
characterized VAMP-1B, an isoform of rat VAMP-1 that is
the result of alternative RNA splicing [18]. Recent studies by
Isenmann et al. demonstrated that the carboxy-terminal do-
main a¡ected by the alternative RNA splicing of human
VAMP-1 in£uences the protein’s sorting. When epitope-
tagged VAMP-1B is expressed in endothelial cells, it is tar-
geted to mitochondria whereas VAMP-1A was targeted to the
plasma membrane and endosomes [19].
This study describes the identi¢cation and characterization
of rat VAMP-2B, an alternatively spliced isoform of VAMP-
2. The predicted amino acid sequence of VAMP-2B results in
a change at the carboxy-terminal end of the protein.
2. Materials and methods
PC12 and AR42J cells were obtained from ATCC (American Type
Culture Collection, Manassas, VA). All materials were obtained from
Sigma Chemical Company unless otherwise indicated.
2.1. Antibodies
Hybridomas producing the mouse monoclonal anti-c-myc antibod-
ies (9E10) were purchased from ATCC. Rabbit polyclonal anti-human
chromogranin-A antiserum was kindly provided by Dr. Daniel T.
O’Connor (University of California, San Diego, CA). Monoclonal
anti-synaptophysin antibodies (SVP-38) were purchased from Sigma.
2.2. PCR cloning and sequencing
A PCR approach as described by Frohman [20] was used to amplify
cDNAs at the 3P-end (3P-RACE) to search for novel isoforms of
VAMP-2. An oligo-dT primer (5P-CCAGTGAGCAGAGTGAC-
GAGGACTCGAGCTCAAGCTTTTTTTTTTTTTTTTT-3P) and rat
pancreatic poly-A RNA were used to create a cDNA library. The
polymerase chain reaction was then performed using a primer repre-
senting a highly conserved sequence present in rat VAMP-2 (5P-
TGAGGTGGTGGACATCATGAGGGTGAAT-3P) (nt 140^167 [5])
and another based on the oligo-dT primer (5P-CCAGTGAGCA-
GAGTGACG-3P). A 495 nt PCR product was obtained and the nu-
cleotide sequence was determined. The nucleotide sequence revealed
di¡erences from the VAMP-2 sequence that would predict a change in
the amino acid sequence at the carboxy-terminal end. Oligonucleotide
primers based on the unique sequences were then used to obtain the
5P-end of the cDNA using the 5P-RACE approach [20]. The cDNA
sequence of the PCR product derived from the 5P-RACE approach
was determined. Finally, oligonucleotides 5P-GGGAGCCAGCGC-
GAGCGGCCGCCGCTGTCA-3P (nt 1^30, Fig. 1) and 5P-CTCT-
ACGTGAGTCAGAACTGCCAATAGCA-3P (nt 548^520, Fig. 1)
based on the 5P- and 3P-RACE approaches were used to obtain a
single PCR product. The entire cloning process including the produc-
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tion of rat pancreatic cDNA and the generation of PCR products as
described above was repeated to ensure reproducibility of the results.
All PCR products were initially subcloned into the EcoRV site of the
pBluescript KS II(+) plasmid vector (Stratagene) [21]. Dideoxy se-
quencing was performed on both DNA strands as described by
Sanger [22] (Sequenase kit, United States Biochemical). Sequencing
was also performed at the Stanford University Protein and Nucleic
Acid Facility using an automated DNA sequencer (Model 373A, PE
Applied Biosystems).
2.3. RNA puri¢cation
Poly-A RNA from tissues for the Northern blots and RACE reac-
tions was prepared as described [23]. Total RNA from tissue culture
cells was prepared utilizing the RNeasy Midi Kit (Qiagen Inc.) ac-
cording to the manufacturer’s instructions. Four con£uent 15 cm
dishes of each respective cell line were used for each preparation.
The quality of the puri¢ed RNA was veri¢ed on a formaldehyde gel
showing clear 28S and 18S bands in the expected ratio of 2:1.
2.4. Ribonuclease protection assay
The ribonuclease protection assay was performed using the RPA II
Kit (Ambion Inc.) according to the manufacturer’s instructions.
[32P]UTP-labeled antisense RNA was generated from nt 55 to 548
of VAMP-2B, which included the open reading frame and part of
the 3P-untranslated region (Fig. 1). An antisense L-actin probe was
generated utilizing a template provided by the manufacturer and was
used as a positive control.
2.5. Protein immunoblotting
Protein immunoblots were prepared as described by Towbin et al.
[24]. Detection was performed using antibodies raised against the
di¡erent VAMP isoforms or the myc-epitope tag. Bu¡er containing
5% non-fat milk, PBS, 0.05% Tween 20 was used in all steps as
described [25]. Detection of the primary antibodies used goat anti-
rabbit or goat anti-mouse antibodies conjugated to horseradish per-
oxidase (Bio-Rad Laboratories) at a dilution of 1:2000, followed by
visualization using enhanced chemiluminescence (ECL, Amersham
Corp.) and Kodak XAR5, X-OMAT ¢lm.
2.6. Transfection of PC12 cells
Myc-epitope tagged VAMP-2 and -2B constructs were made using
the PJ3M vector that was kindly provided by Dr. J. Cherno¡ (Fox
Chase Cancer Center, Philadelphia, PA) [26]. The entire open reading
frame for each VAMP isoform was subcloned from the pBluescript
KS II+ vector into PJ3M using the restriction enzymes EcoRI and
ClaI. DNA sequencing con¢rmed the VAMP inserts to be in frame
with the sequence encoding the myc-epitope and resulted in the addi-
tion of 25 amino acids [NH2-MEQKLISEEDLSRGSPGELEFAT-
PA-COOH] at the amino-terminal end. PC12 cells grown to 50%
con£uence were cotransfected with 1^2 Wg of the PJ3M construct
along with 0.5 Wg of a plasmid containing the neomycin resistance
gene using Lipofectamine (Life Technologies, Inc.) according to the
manufacturer’s instructions. Resistant clones were selected using 0.5
mg/ml of G-418 (Life Technologies Inc.). Positive clones were identi-
¢ed using protein immunoblotting. In addition to the stably trans-
fected cell lines, transiently transfected PC12 and COS-7 cells were
also used.
2.7. Subcellular fractionation
Subcellular fractionation was performed as previously described
[27]. The cells were grown in a 15 cm plate until nearly con£uent,
rinsed, and washed o¡ the plate with PBS. The cells were then col-
lected by centrifugation for 5 min at 600Ug. The cell pellet was
resuspended in 0.8 ml homogenization bu¡er and homogenized with
8 strokes in a custom made ball bearing cell cracker with a clearance
of 0.0004 inch (10 Wm). The homogenate was centrifuged for 10 min
at 700Ug. 200^400 Wl of the supernatant was layered over the follow-
ing gradients.
Glycerol (velocity) gradient: Sample preparation was performed as
described above using a homogenization bu¡er consisting of 150 mM
NaCl, 1 mM EGTA, 1 mM MgCl2, 10 mM HEPES, pH 7.4. A
continuous 5^25% glycerol gradient was generated utilizing the
Auto-Densi Flow IIC (Buchler Instruments). The gradients were cen-
trifuged in a SW65 Ti rotor (Beckman Instruments) for 30 min at
54 000 rpm, 4‡C. 0.5 ml fractions were collected from the top of the
tube using the Auto-Densi Flow IIC.
Sucrose (equilibrium density) gradients: The sample preparation
was performed as described above using a homogenization bu¡er
consisting of 0.25 M sucrose, 4 mM HEPES pH 7.4 and 1 mM
MgCl2. A continuous 0.5^1.7 M sucrose gradient was generated as
described for the glycerol gradient. The samples were centrifuged in a
SW41 rotor (Beckman Instruments) for 20 h at 25 000 rpm, 4‡C,
followed by the collection of 1 ml fractions. 45 Wl of each fraction
was loaded on a 12% SDS polyacrylamide gel and prepared for pro-
tein immunoblotting as described above.
3. Results
3.1. Cloning and sequencing of VAMP-2B
Low stringency Northern blots using a probe derived from
rat VAMP-2 cDNA suggested the presence of other related
VAMP isoforms (data not shown). A PCR based approach
produced a product with a nucleotide sequence that di¡ered
from VAMP-2 at the 3P-end of the open reading frame. The
entire open reading frame of the new isoform, named VAMP-
2B, could be obtained in a single polymerase chain reaction
from a rat pancreatic cDNA library (Fig. 1, nt 1^548, under-
lined). Comparisons with the published rat and human
VAMP-2 sequence [5,28] revealed that the predicted amino
acid sequence for VAMP-2B is identical to VAMP-2 through
exon 4, whereupon the protein terminates with 24 novel ami-
no acids at the carboxy-terminal end (Fig. 1). We have pre-
viously demonstrated that VAMP-1 isoforms are produced by
alternative RNA splicing which results in the retention of an
intron and predicts changes at the carboxy-terminal end [18].
Examination of the nucleotide sequence speci¢c for VAMP-
2B revealed a potential 5P-donor splice site [29,30]. To deter-
mine whether the VAMP-2B speci¢c sequence is derived from
a retained intron, PCR analysis of the rat genomic VAMP-2
gene was performed. Oligonucleotide primers derived from
the novel sequence of VAMP-2B and exon 5 of the VAMP-
2 gene were used to obtain a 597 nt PCR product from rat
genomic DNA. Analysis of the nucleotide sequence for known
intron/exon boundary sequences revealed that the VAMP-2B
speci¢c sequence was indeed a retained intron (Fig. 1, nt 401^
1001) [29,30].
3.2. Ribonuclease protection assays
Northern blots of RNA derived from a variety of rat tissues
were performed using a VAMP-2B speci¢c probe (data not
shown). A 3000 nt transcript is seen in pancreas, heart, kid-
ney, liver, spleen, parotid, and brain. Compared to the pre-
viously described 2400 nt transcript for VAMP-2, the ob-
served VAMP-2B transcript was consistent with that of a
retained intron of 601 nt. The presence of VAMP-2B tran-
scripts was examined using ribonuclease protection assays of
pancreatic and brain RNA (Fig. 2). The ribonuclease protec-
tion assay used an antisense probe that is able to distinguish
between VAMP-2 and -2B transcripts. Two dominant pro-
tected fragments were observed in the pancreas, a 346 nt frag-
ment consistent with the VAMP-2 transcript and a 494 nt
fragment consistent with that of VAMP-2B. In contrast, brain
RNA produced only a single protected fragment consistent
with VAMP-2 (Fig. 2). This demonstrated that the relative
amounts of VAMP-2B to VAMP-2 transcripts is signi¢cantly
higher in the pancreas compared to the brain.
Ribonuclease protection assays were also used to assess the
presence of the VAMP-2B transcript in PC12 and AR42J
cells. AR42J cells are a rat cell line derived from the acinar
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cell of the pancreas [31]. PC12 cells are a neuroendocrine cell
line derived from the rat adrenal medulla and have been com-
monly used to study VAMP sorting. RNA antisense probes
representing VAMP-2B resulted in protected fragments con-
sistent with endogenous VAMP-2 and VAMP-2B in AR42J
and PC12 cells. Similar to the pancreas, ribonuclease pro-
tected transcripts consistent with VAMP-2 were much more
abundant than VAMP-2B. In contrast to the brain, PC12 cells
exhibited protected fragments consistent with both VAMP-2
isoforms (Fig. 2B).
3.3. Subcellular distribution of VAMPs-2 and -2B
The subcellular distribution of VAMP-2 and -2B was ex-
amined to determine whether di¡erences in sorting existed
between the alternatively spliced isoforms. PC12 cells were
used because these cells have often been used as a model
system to examine VAMP sorting [15,32^34]. In addition,
ribonuclease protection assays also established the presence
of the VAMP-2B transcript in PC12 cells. Thus it is likely
that PC12 cells would possess the necessary factors for
sorting VAMP-2B. A myc-epitope was appended to the
amino-terminal end of VAMP-2B and expressed in PC12
cells using both stable and transient transfections. The sub-
cellular distribution of myc-VAMP-2B was compared to that
of endogenous VAMP-2 using equilibrium and velocity sed-
imentation approaches for subcellular fractionation. Both of
these approaches were previously used to assess the distribu-
tion of VAMPs in endosomes, secretory granules, and syn-
aptic vesicles [27,32]. Equilibrium gradients using sucrose are
able to resolve the endosomal and synaptic vesicle compart-
ments from the secretory granules. Myc-VAMP-2B colocal-
ized with the endosomal and synaptic vesicle fractions. No
di¡erence in the distribution of myc-VAMP-2B from endog-
enous VAMP-2 was seen (Fig. 3A). Glycerol velocity gra-
dients were also employed to obtain better resolution be-
tween endosomes and synaptic vesicles. Again, myc-VAMP-
2B exhibited the same distribution as endogenous VAMP-2
(Fig. 3B). The resolution of the sucrose and glycerol gra-
dients was validated when the expected distribution for chro-
mogranin A (secretory granules), transferrin receptor (endo-
somes), and synaptophysin (synaptic vesicles) was obtained
(Fig. 3A,B).
Fig. 1. The VAMP-2B cDNA clone represented by nt 1^548 (A, underlined) was derived from a pancreatic cDNA library using primers A and
B (B) and includes the whole open reading frame. The remaining part of the sequence was derived from a rat kidney genomic DNA library us-
ing primers C and D (B) and is represented by nt 446^1042. Di¡erences in the amino acid sequence compared to VAMP-2 are on the carboxy-
terminal end where the VAMP-2 cDNA sequence normally encoded by exon-5 is interrupted by a novel sequence that replaces the carboxy-ter-
minal ¢ve amino acids of VAMP-2 (VYFST) with 24 amino acids (GEWSRSGQGPFPGEVEGFPVGSGL). The ¢rst and last two nucleotides
of the intron sequence are shown in bold. The intron sequence is depicted in lower case letters. The sequence has been deposited in the EMBL
sequence database under accession number AJ133104.
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4. Discussion
This study characterizes VAMP-2B, an isoform of VAMP-2
that is generated by alternative RNA splicing. Alternative
RNA splicing resulting in a transcript with a retained intron
often occurs at the 3P-end and has also been described for
bovine growth hormone [35], e¡ector cell protease receptor-
1 [36], myelin oligodendrocyte glycoprotein [37] and tau [38].
Intron retention was also recently reported for VAMP-1B,
where a transcript with a retained intron was expressed in
the spleen, liver, kidney, pancreas, and parotid, whereas in
the brain and heart, only the fully spliced transcript of
VAMP-1 is present [18]. In contrast to VAMP-1 and -1B, in
which only one of the isoforms was expressed in each tissue,
ribonuclease protection assays demonstrated the presence of
VAMP-2 and -2B in the AR42J and PC12 cell lines and the
pancreas.
The carboxy-terminal end of VAMP-2B is predicted to re-
sult in the replacement of the ¢ve uncharged carboxy-terminal
amino acids with 24 amino acids. The additional amino acids
provided by VAMP-2B includes four glutamic acid residues
and one arginine, which would produce a signi¢cant change in
the charge and structure of the carboxy-terminal end. In com-
parison, VAMP-1B di¡ers from VAMP-1A in the shortening
of the hydrophobic domain by four amino acids and the ad-
dition of two basic residues.
Because the previously published work by Ossig et al. sug-
gested a role for VAMP sorting at the carboxy-terminal end,
we examined whether alternative RNA splicing of VAMP-2s
in£uences the protein’s sorting. In addition, studies published
by Isenmann et al. [19] while this work was in progress pro-
vided further support that VAMP-2B may be sorted di¡er-
ently from VAMP-2. Because untransfected PC12 cells express
VAMP-2B RNA as determined by the ribonuclease protection
assays, they were chosen to study the e¡ects of the alternative
RNA splicing. When myc-VAMP-2B was expressed from
PC12 cells, it colocalized with the endogenous VAMP-2 iso-
form on equilibrium and velocity gradients. Controls for these
experiments indicated that a signi¢cant di¡erence in the sub-
cellular distribution of VAMP-2 and -2B should have been
detected. Clearly, the sorting of myc-VAMP-2B to a compart-
ment as large as mitochondria as seen for VAMP-1B would
have been detected. These results indicate that the VAMP-2B
transcript does not encode a protein that is sorted di¡erently
from VAMP-2 in PC12 cells.
Fig. 3. Protein immunoblots of subcellular fractions derived from
equilibrium sucrose density (A) and glycerol velocity gradients (B).
Colocalization of the transfected tagged VAMP-2B isoform (V2B-
myc) with the endogenous VAMP-2 protein (V2) is seen. Chromo-
granin A (CgA), synaptophysin (SVP-38) and transferrin receptor
(TFR). The indicated fractions represent the lowest (1) to the high-
est (11) density.
Fig. 2. A: Ribonuclease protection assays using a complementary
antisense RNA derived from a VAMP-2B clone (Fig. 1, nt 55^548)
were performed with brain and pancreatic poly-A RNA. A 346 nt
protected fragment expected for the VAMP-2 transcript is present
in brain and pancreas (**). A 494 nt protected fragment consistent
with VAMP-2B is seen only in the pancreas (*). Sequences derived
from the vector account for the larger size of the probe. 0.3 Wg of
brain and 10 Wg of pancreatic poly-A RNA were used. B: Ribonu-
clease protection assays of RNA derived from AR42J cells, PC12
cells transfected with myc-VAMP-2B cDNA, wild-type PC12 cells,
and rat brain were performed using the VAMP-2B speci¢c antisense
probe. The V2B protected fragment in PC12-V2B-myc cells repre-
sents the endogenous VAMP-2B and the transfected myc-VAMP-
2B. The mobility of the protected fragments are VAMP-2 = V2;
VAMP-2B = V2B.
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